- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: July 2026
Elacestrant – July 2026
- Tablet 86 mg (as dihydrochloride)
- Tablet 345 mg (as dihydrochloride)
Public Summary Documents
Last updated
13 November 2026
